Related Experiment Video
Updated: May 20, 2026
11:57
Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
Cystatin C in Alzheimer's disease
1Departments of Psychiatry, Biochemistry, and Molecular Pharmacology, Center for Dementia Research, Nathan S. Kline Institute, New York University School of Medicine, Orangeburg NY, USA.
Frontiers in Molecular Neuroscience
|July 12, 2012
Summary
Cystatin C (CysC) protects brain cells by binding amyloid-beta (Aβ) and inhibiting its toxic aggregation, suggesting CysC is a potential therapeutic agent for Alzheimer's disease (AD). Reduced CysC levels in AD brains may increase neuronal vulnerability.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Cystatin C (CysC) levels change in neurological disorders, and a gene polymorphism is linked to Alzheimer's disease (AD) risk.
- AD pathology involves amyloid-beta (Aβ) deposition, tau tangles, and neurodegeneration.
- CysC co-localizes with Aβ in amyloid plaques and vascular walls in AD brains.
Purpose of the Study:
- To review the neuroprotective roles of CysC in Alzheimer's disease.
- To explore the clinical relevance of CysC as a potential therapeutic agent for AD.
Main Methods:
- In vitro studies on CysC binding to Aβ and its effect on Aβ aggregation.
- In vivo studies in Aβ-depositing transgenic mice examining CysC-Aβ association and plaque formation.
- Analysis of CysC-Aβ association in human brain and cerebrospinal fluid (CSF) from AD patients and controls.
Main Results:
- CysC binds Aβ, inhibiting oligomerization and fibril formation in vitro.
- CysC associates with soluble Aβ in vivo, reducing Aβ plaque formation in mice.
- CysC protects neuronal cells from Aβ-induced toxicity.
- Reduced CysC levels in AD brains correlate with increased neuronal vulnerability.
Conclusions:
- CysC exhibits significant neuroprotective roles in Alzheimer's disease.
- CysC's ability to inhibit Aβ aggregation and protect neurons highlights its therapeutic potential for AD.
- Therapeutic strategies targeting CysC levels may help prevent neurodegeneration in AD.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...